Frank Berthold
Overview
Explore the profile of Frank Berthold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
5549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Zogchel L, Decarolis B, van Wezel E, Zappeij-Kannegieter L, Gelineau N, Schumacher-Kuckelkorn R, et al.
J Exp Clin Cancer Res
. 2024 Dec;
43(1):331.
PMID: 39722049
Background: Liquid biopsies offer less burdensome sensitive disease monitoring. Bone marrow (BM) metastases, common in various cancers including neuroblastoma, is associated with poor outcomes. In pediatric high-risk neuroblastoma most patients...
2.
Farrag A, Ghazaly M, Mohammed K, Volland R, Hero B, Berthold F
BMC Pediatr
. 2023 Sep;
23(1):443.
PMID: 37670249
Background: Substantial progress has been achieved in managing childhood cancers in many high-income countries (HICs). In contrast, survival rates in lower-middle-income countries (LMICs) are less favorable. Here, we aimed to...
3.
Bechmann N, Moskopp M, Constantinescu G, Stell A, Ernst A, Berthold F, et al.
J Clin Endocrinol Metab
. 2023 Aug;
109(2):471-482.
PMID: 37647861
Context: Sexual dimorphism has direct consequences on the incidence and survival of cancer. Early and accurate diagnosis is crucial to improve prognosis. Objective: This work aimed to characterized the influence...
4.
Butzer S, Krug B, Reisberg M, Fuchs J, Warmann S, Hubertus J, et al.
Pediatr Blood Cancer
. 2023 Aug;
70(10):e30605.
PMID: 37534915
Background: The pretreatment International Neuroblastoma Risk Group Staging System (INRGSS) discriminates localized tumors L1/L2 depending on the absence/presence of image-defined risk factors (IDRFs) at diagnosis. Referring to this new staging...
5.
Rosswog C, Fassunke J, Ernst A, Schomig-Markiefka B, Merkelbach-Bruse S, Bartenhagen C, et al.
Br J Cancer
. 2023 Feb;
128(8):1559-1571.
PMID: 36807339
Background: Genomic alterations of the anaplastic lymphoma kinase gene (ALK) occur recurrently in neuroblastoma, a pediatric malignancy of the sympathetic nervous system. However, information on their development over time has...
6.
Danzer M, Terzer T, Berthold F, Faldum A, Schmidt R
Biom J
. 2022 Feb;
64(2):312-342.
PMID: 35152459
Existing methods concerning the assessment of long-term survival outcomes in one-armed trials are commonly restricted to one primary endpoint. Corresponding adaptive designs suffer from limitations regarding the use of information...
7.
Roderwieser A, Sand F, Walter E, Fischer J, Gecht J, Bartenhagen C, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-20.
PMID: 35100718
Purpose: Telomere maintenance is a hallmark of high-risk neuroblastoma; however, the contribution of telomerase and alternative lengthening of telomeres (ALT) to clinical phenotypes has remained unclear. We aimed to determine...
8.
Hoemberg M, Schwenzfeur R, Berthold F, Simon T, Hero B
Pediatr Blood Cancer
. 2021 Sep;
69(2):e29374.
PMID: 34569150
Purpose: 13-cis-Retinoic acid (13-cisRA) is used as a postconsolidation treatment in patients with high-risk neuroblastoma. Hypercalcemia is a known side effect of retinoids. Frequency, symptoms, treatment, and risk factors for...
9.
Berthold F, Ernst A, Ackermann S, Bartenhagen C, Christiansen H, Hero B, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503173
Background: To identify variables predicting outcome in neuroblastoma patients assigned to the high-risk group solely by the presence of oncogene amplification (MNA). Methods: Clinical characteristics, genomic information, and outcome of...
10.
Berthold F, Spix C, Erttmann R, Hero B, Michaelis J, Treuner J, et al.
JNCI Cancer Spectr
. 2021 Jul;
5(4).
PMID: 34240006
Background: Neuroblastoma screening aims to reduce neuroblastoma-related mortality. A controlled trial showed no reduction in stage 4 disease incidence and preliminary mortality data. This article presents epidemiologic and clinical data...